FDA Grants Priority Review To Syndax's Revuforj For R/R MNPM1 Acute Myeloid Leukemia Treatment
25/6 03:49
(RTTNews) - Syndax Pharmaceuticals (SNDX) announced that the U.S. Food and Drug Administration has granted Priority Review for its supplemental New Drug Application (sNDA) for Revuforj (revumenib) for the treatment of relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid...